Pasar al contenido principal

ONCOPROTEINAS DE LA FAMILIA VAV: REGULACION, FUNCIONES PATOFISIOLOGICAS Y POTENCIAL TERAPEUTICO

SAF2015-64556-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia

  • Robles-Valero, Javier
  • Lorenzo-Martín, L. Francisco
  • Menacho Márquez, Mauricio
  • Fernández-Pisonero, Isabel
  • Abad, Antonio
  • Camós, Mireia
  • Toribio, María Luisa
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
  • Bustelo, Xose R.
Rho guanine exchange factors (GEFs), the enzymes that stimulate Rho GTPases, are deemed as potential therapeutic targets owing to their protumorigenic functions. However, the understanding of the spectrum of their pathobiological roles in tumors is still very limited. We report here that the GEF Vav1 unexpectedly possesses tumor-suppressor functions in immature T cells. This function entails the noncatalytic nucleation of complexes between the ubiquitin ligase Cbl-b and the intracellular domain of Notch1 (ICN1) that favors ICN1 ubiquitinylation and degradation. Ablation of Vav1 promotes ICN1 signaling and the development of T cell acute lymphoblastic leukemia (T-ALL). The downregulation of Vav1 is essential for the pathogenesis of human T-ALL of the TLX+ clinical subtype, further underscoring the suppressor role of this pathway, X.R.B. is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society Against Cancer. L.E. (PI13/00448), A.B. (SAF2013-40922-R, RD12/0036/0054), and M.L.T. (SAF2013-44857-R, RD12/0036/0075) are supported by MINECO grants. Spanish funding is partially supported by the European Regional Development Fund. We thank M. Blázquez for laboratory work, R. Valiente for ChIP-seq analyses, M. Dosil for comments on the manuscript, and CIC facilities' personnel for technical assistance
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

  • Garmendia, Irati
  • Pajares Villandiego, María Josefa
  • Hermida-Prado, Francisco
  • Ajona, Daniel
  • Bértolo, Cristina
  • Sáinz, Cristina
  • Lavín, Amaya
  • Remírez, Ana
  • Valencia, Karmele
  • Moreno, Haritz
  • Ferrer, Irene
  • Behrens, Carmen
  • Cuadrado, Myriam
  • Paz-Ares, Luis
  • Bustelo, Xosé R.
  • Gil-Bazo, Ignacio
  • Alameda, Daniel
  • Lecanda, Fernando
  • Calvo, Alfonso
  • Felip, Enriqueta
  • Sánchez-Céspedes, Montse
  • Wistuba, Ignacio
  • Granda-Díaz, Rocío
  • Rodrigo, Juan Pablo
  • García-Pedrero, Juana María
  • Pío, Rubén
  • Montuenga, Luis M.
  • Agorreta Arrazubi, Jackeline
Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.)., Rationale: the characterization of new genetic alterations is essential to assign effective personalized therapies in non-small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in a significant subset of patients with lung cancer. Objectives: to evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) genetic alteration as a therapeutic target and predictive biomarker of response to dasatinib in NSCLC. Methods: functional significance was evaluated by in vivo models of NSCLC and metastasis and patient-derived xenografts. The efficacy of pharmacological and genetic (CRISPR [clustered regularly interspaced short palindromic repeats]/Cas9 [CRISPR-associated protein 9]) YES1 abrogation was also evaluated. In vitro functional assays for signaling, survival, and invasion were also performed. The association between YES1 alterations and prognosis was evaluated in clinical samples. Measurements and Main Results: we demonstrated that YES1 is essential for NSCLC carcinogenesis. Furthermore, YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. YES1 effects were mainly driven by mTOR (mammalian target of rapamycin) signaling. Interestingly, cell lines and patient-derived xenograft models with YES1 gene amplifications presented a high sensitivity to dasatinib, an SFK inhibitor, pointing out YES1 status as a stratification biomarker for dasatinib response. Moreover, high YES1 protein expression was an independent predictor for poor prognosis in patients with lung cancer. Conclusions: YES1 is a promising therapeutic target in lung cancer. Our results provide support for the clinical evaluation of dasatinib treatment in a selected subset of patients using YES1 status as predictive biomarker for therapy., Supported by Fundación para la Investigación Médica Aplicada (FIMA), Spanish Ministry of Economy and Innovation and Fondo de Investigación Sanitaria Fondo Europeo de Desarrollo Regional grants 12/02040, PI13/00806, PI16/01821, PI16/00280, RTICC RD12/0036/0040, and SAF2015-6455-R; Centro de Investigación Biomédica en Red de Cáncer grants CB16/12/00390, CB16/12/00390, CB16/12/00442, and CB16/12/00443; Asociación Española Contra el Cáncer (AECC) Scientific Foundation grant GCB14-2170; Bristol-Myers Squibb (preclinical research agreement); AECC and a fellowship from the Basque Government (I.G.); the Castilla-León Government grant CSI049 U16 , the Ministry of Economy and Competitiveness grant SAF2015-64556-R , the Fundación Ramón Areces, Worldwide Cancer Research grant 14-1248 , and AECC Scientific Foundation grant GC16173472GARC (X.R.B.); and the Spanish Ministry of Science, Innovation and Universities (MCIU, RTI 2018-094507-B-100), La Caixa Foundation and Caja Navarra Foundation (F.L.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Characterization of novel molecular mechanisms favoring rac1 membrane translocation

  • Castro-Castro, Antonio
  • Muriel, Olivia
  • Pozo, Miguel A. del
  • Bustelo, Xosé R.
The Rac1 GTPase plays key roles in cytoskeletal organization, cell motility and a variety of physiological and disease-linked responses. Wild type Rac1 signaling entails dissociation of the GTPase from cytosolic Rac1-Rho GDP dissociation inhibitor (GDI) complexes, translocation to membranes, activation by exchange factors, effector binding, and activation of downstream signaling cascades. Out of those steps, membrane translocation is the less understood. Using transfections of a expression cDNA library in cells expressing a Rac1 bioreporter, we previously identified a cytoskeletal feedback loop nucleated by the F-actin binding protein coronin 1A (Coro1A) that promotes Rac1 translocation to the plasma membrane by facilitating the Pak-dependent dissociation of Rac1-Rho GDI complexes. This screening identified other potential regulators of this process, including WDR26, basigin, and TMEM8A. Here, we show that WDR26 promotes Rac1 translocation following a Coro1A-like and Coro1A-dependent mechanism. By contrast, basigin and TMEM8A stabilize Rac1 at the plasma membrane by inhibiting the internalization of caveolin-rich membrane subdomains. This latter pathway is F-actin-dependent but Coro1A-, Pak- and Rho GDI-independent., XRB has been supported by grants from the Spanish Ministry of Economy and Competitiveness (RD12/0036/0002, SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, Consejería de Educación of the Junta de Castilla y León (CSI049U16), and Fundación Científica Asociación Española contra el Cáncer (GD16173472GARC). Funding from both the Spanish Ministry of Economy and Competitiveness and Junta de Castilla y León is partially contributed by the European Regional Development Fund., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vav proteins are key regulators of card9 signaling for innate antifungal immunity

  • Roth, Susanne
  • Bergmann, Hanna
  • Jaeger, Martin
  • Yeroslaviz, Assa
  • Neumann, Konstantin
  • Koenig, Paul-Albert
  • Prazeres da Costa, Clarissa
  • Vanes, Lesley
  • Kumar, Vinod
  • Johnson, Melissa
  • Menacho-Márquez, Mauricio
  • Habermann, Bianca
  • Tybulewicz, Victor L.
  • Netea, Mihai
  • Bustelo, Xosé R.
  • Ruland, Jürgen
Fungal infections are major causes of morbidity and mortality, especially in immunocompromised individuals. The innate immune system senses fungal pathogens through Syk-coupled C-type lectin receptors (CLRs), which signal through the conserved immune adaptor Card9. Although Card9 is essential for antifungal defense, the mechanisms that couple CLR-proximal events to Card9 control are not well defined. Here, we identify Vav proteins as key activators of the Card9 pathway. Vav1, Vav2, and Vav3 cooperate downstream of Dectin-1, Dectin-2, and Mincle to engage Card9 for NF-κB control and proinflammatory gene transcription. Although Vav family members show functional redundancy, Vav1/2/3 mice phenocopy Card9 animals with extreme susceptibility to fungi. In this context, Vav3 is the single most important Vav in mice, and a polymorphism in human VAV3 is associated with susceptibility to candidemia in patients. Our results reveal a molecular mechanism for CLR-mediated Card9 regulation that controls innate immunity to fungal infections., This work was supported by research grants from the Helmholtz Alliance Preclinical Comprehensive Cancer Center, the DFG (SFB 1054 and RU 695/6-1), and an ERC Advanced Grant (FP7, grant agreement 322865) (to J.R.). The work of X.R.B. has been supported by grants from the Spanish Ministry of Economy and Competitiveness (RD12/0036/0002 and SAF2015-64556-R), Worldwide Cancer Research (14-1248), and the Ramón Areces Foundation. M.G.N. was supported by an ERC Consolidator Grant (310372). V.L.T. was supported by the Francis Crick Institute which receives its core funding from the MRC (FC001194), Cancer Research UK (FC001194) and the Wellcome Trust (FC001194)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Focal accumulation of preribosomes outside the nucleolus during metaphase-anaphase in budding yeast

  • Moriggi, Giulia
  • Gaspar, Sonia G.
  • Nieto, Blanca
  • Bustelo, Xosé R.
  • Dosil, Mercedes
Saccharomyces cerevisiae contains one nucleolus that remains intact in the mother-cell side of the nucleus throughout most of mitosis. Based on this, it is assumed that the bulk of ribosome production during cell division occurs in the mother cell. Here, we show that the ribosome synthesis machinery localizes not only in the nucleolus but also at a center that is present in the bud side of the nucleus after the initiation of mitosis. This center can be visualized by live microscopy as a punctate body located in close proximity to the nuclear envelope and opposite to the nucleolus. It contains ribosomal DNA (rDNA) and precursors of both 40S and 60S ribosomal subunits. Proteins that actively participate in ribosome synthesis, but not functionally defective variants, accumulate in that site. The formation of this body occurs in the metaphase-to-anaphase transition when discrete regions of rDNA occasionally exit the nucleolus and move into the bud. Collectively, our data unveil the existence of a previously unknown mechanism for preribosome accumulation at the nuclear periphery in budding yeast. We propose that this might be a strategy to expedite the delivery of ribosomes to the growing bud., This work was supported by the Spanish Ministry of Economy and Competitiveness (BFU2014-52729-P to M.D.; SAF2015-64556-R and CB16/12/00351 to X.R.B.), the Junta of Castilla y León (CSI049U16), Worldwide Cancer Research (14-1248 to X.R.B.) and the Ramón Areces Foundation. G.M. and B.N. have been supported by graduate student contracts from the University of Salamanca and Santander Bank. S.G.G. has been supported by a contract on the BFU2014-52729-P grant. Spanish funding to M.D. and X.R.B. is partially contributed by the European Regional Development Fund., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ribosome biogenesis and cancer: basic and translational challenges

  • Bustelo, Xosé R.
  • Dosil, Mercedes
Increasing evidence suggests that alterations in ribosome biogenesis (RiBi) confer competitive advantages to cancer cells. This has led to the discovery of regulatory layers mediated by signaling proteins, oncoproteins, and tumor suppressors whose deregulation leads to increased RiBi rates in cancer cells. In addition to boosting protein synthesis, these alterations probably contribute to shape the protumorigenic proteome of cancer cells. Mutations negatively affecting RiBi are also unexpectedly found in some spontaneous and ribosomopathy-associated tumors. The advantages provided by these genetic lesions to cancer cells remain unsettled as yet. Efforts are being made nowadays to exploit RiBi-associated vulnerabilities and tumor suppressor pathways to design new therapeutic avenues. In this review, we will summarize the main developments and pending challenges in this research area., Work in XRB lab is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society Against Cancer. Work in MD lab is supported by a MINECO grant (BFU2014-52729-P). Spanish funding is partially cosponsored by the European Regional Development Fund., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights into the Vav1 activation cycle in lymphocytes

  • Barreira, María
  • Rodríguez-Fdez, Sonia
  • Bustelo, Xosé R.
Vav1 is a hematopoietic-specific Rho GDP/GTP exchange factor and signaling adaptor. Although these activities are known to be stimulated by direct Vav1 phosphorylation, little information still exists regarding the regulatory layers that influence the overall Vav1 activation cycle. Using a collection of cell models and activation-mimetic Vav1 mutants, we show here that the dephosphorylated state of Vav1 in nonstimulated T cells requires the presence of a noncatalytic, phospholipase Cγ1–Slp76-mediated inhibitory pathway. Upon T cell stimulation, Vav1 becomes rapidly phosphorylated via the engagement of Lck and, to a much lesser extent, other Src family kinases and Zap70. In this process, Lck, Zap70 and the adaptor protein Lat contribute differently to the dynamics and amplitude of the Vav1 phosphorylated pool. Consistent with a multiphosphosite activation mechanism, the optimal stimulation of Vav1 can only be recapitulated by the combination of several activation-mimetic phosphosite mutants. The analysis of these mutants has also unveiled the presence of different Vav1 signaling competent states that are influenced by phosphosites present in the N- and C-terminal domains of the protein., X.R.B. is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society against Cancer (GC16173472GARC). M.B. and S.R-F. salaries have been supported by a JAE-Predoc (CSIC) and MINECO FPI (BES-2013-063573) contracts for graduate students, respectively. Funding from MINECO is partially contributed by the European Regional Development Fund., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes

  • Mendoza, Pilar
  • Martínez-Martín, Nuria
  • Bovolenta, Paola
  • Reyes-Garau, Diana
  • Hernansanz-Agustín, Pablo
  • Delgado, Pilar
  • Díaz-Muñoz, Manuel D.
  • Oeste, Clara L.
  • Fernández-Pisonero, Isabel
  • Castellano, Esther
  • Martínez-Ruiz, Antonio
  • Alonso-López, D.
  • Santos de Dios, Eugenio
  • Bustelo, Xosé R.
  • Kurosaki, Tomohiro
  • Alarcón, Balbino
Upon antigen recognition within peripheral lymphoid organs, B cells interact with T cells and other immune cells to transiently form morphological structures called germinal centers (GCs), which are required for B cell clonal expansion, immunoglobulin class switching, and affinity maturation. This process, known as the GC response, is an energetically demanding process that requires the metabolic reprogramming of B cells. We showed that the Ras-related guanosine triphosphate hydrolase (GTPase) R-Ras2 (also known as TC21) plays an essential, nonredundant, and B cell–intrinsic role in the GC response. Both the conversion of B cells into GC B cells and their expansion were impaired in mice lacking R-Ras2, but not in those lacking a highly related R-Ras subfamily member or both the classic H-Ras and N-Ras GTPases. In the absence of R-Ras2, activated B cells did not exhibit increased oxidative phosphorylation or aerobic glycolysis. We showed that R-Ras2 was an effector of both the B cell receptor (BCR) and CD40 and that, in its absence, B cells exhibited impaired activation of the PI3K-Akt-mTORC1 pathway, reduced mitochondrial DNA replication, and decreased expression of genes involved in glucose metabolism. Because most human B cell lymphomas originate from GC B cells or B cells that have undergone the GC response, our data suggest that R-Ras2 may also regulate metabolism in B cell malignancies., This work was supported by grants from the European Research Council ERC 2013–Advanced Grant 334763 NOVARIPP (to B.A.), the Ministerio de Economía y Competitividad [SAF2016-76394-R (to B.A.) and SAF2015-64556-R (to X.R.B.)], the Fondo de Investigaciones Sanitarias [FIS PI16/02137 (to E.S.)], the Instituto de Salud Carlos III RTICC [RD12/0036/0001 (to E.S.)], the Castilla-León Government [SA043U16 (to E.S.) and BIO/SA01/15, CSI049U16 (to X.R.B.)], the Worldwide Cancer Research [14-1248 (to X.R.B.)], the Fundación Ramón Areces, and the Fundación Científica de la Asociación Española Contra el Cáncer [GC16173472GARC (to B.A. and X.R.B.)]., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación

Phosphatidylinositol monophosphates regulate optimal Vav1 signaling output

  • Rodríguez-Fdez, Sonia
  • Citterio, Carmen
  • Lorenzo-Martín, L. Francisco
  • Baltanás-Copado, Jesús
  • Llorente-González, Clara
  • Corbalán-García, Senena
  • Vicente-Manzanares, Miguel
  • Bustelo, Xosé R.
Phosphatidylinositol–5 phosphate (PI5P) and other mono-phosphoinositides (mono-PIs) play second messenger roles in both physiological and pathological conditions. Despite this, their intracellular targets and mechanisms of action remain poorly characterized. Here, we show that Vav1, a protein that exhibits both Rac1 GDP/GTP exchange and adaptor activities, is positively modulated by PI5P and, possibly, other mono-PIs. Unlike other phospholipid–protein complexes, the affinity and specificity of the Vav1–lipid interaction entail a new structural solution that involves the synergistic action of the Vav1 C1 domain and an adjacent polybasic tail. This new regulatory layer, which is not conserved in the Vav family paralogs, favors the engagement of optimal Vav1 signaling outputs in lymphocytes., X.R.B. is supported by grants from the Castilla–León Government (CSI049U16, CLC–2017–01); the Spanish Ministry of Science, Innovation, and Universities (MSIU) (SAF2015–64556–R, RTI2018–096481–B–I00); and the Spanish Association against Cancer (GC16173472GARC). X.R.B.’s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Ministry of Education of the Castilla–León Government (CLC–2017–01). S.C.-G. is supported by grants from MISIU (BFU2017–87222–P) and Séneca Región de Murcia Foundation (19409/PI/14). M.V.-M. is supported by grants from the MISIU (SAF2017–87408–R) and the Spanish Association against Cancer (2018–IDEAS18018VICE). S.R.-F.’s and L.F.L.-M.’s contracts were supported by funding from the MISIU (SR-F, BES–2013–063573) and the Spanish Ministry of Education, Culture, and Sports (LFL–M, FPU13/02923), respectively. Both Spanish and Castilla–León government-associated funding is partially supported by the European Regional Development Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms

  • Lorenzo-Martín, L. Francisco
  • Citterio, Carmen
  • Menacho-Márquez, Mauricio
  • Conde, Javier
  • Larive, Romain M.
  • Rodríguez-Fdez, Sonia
  • García-Escudero, Ramón
  • Robles-Valero, Javier
  • Cuadrado, Myriam
  • Fernández-Pisonero, Isabel
  • Dosil, Mercedes
  • Sevilla, Mª Ángeles
  • Montero, María J.
  • Fernández-Salguero, Pedro M.
  • Paramio, Jesús M.
  • Bustelo, Xosé R.
The bidirectional regulation of epithelial–mesenchymal transitions (EMT) is key in tumorigenesis. Rho GTPases regulate this process via canonical pathways that impinge on the stability of cell-to-cell contacts, cytoskeletal dynamics, and cell invasiveness. Here, we report that the Rho GTPase activators Vav2 and Vav3 utilize a new Rac1-dependent and miR-200c-dependent mechanism that maintains the epithelial state by limiting the abundance of the Zeb2 transcriptional repressor in breast cancer cells. In parallel, Vav proteins engage a mir-200c-independent expression prometastatic program that maintains epithelial cell traits only under 3D culture conditions. Consistent with this, the depletion of endogenous Vav proteins triggers mesenchymal features in epithelioid breast cancer cells. Conversely, the ectopic expression of an active version of Vav2 promotes mesenchymal-epithelial transitions using E-cadherin-dependent and independent mechanisms depending on the mesenchymal breast cancer cell line used. In silico analyses suggest that the negative Vav anti-EMT pathway is operative in luminal breast tumors. Gene signatures from the Vav-associated proepithelial and prometastatic programs have prognostic value in breast cancer patients., XRB is supported by grants from the Castilla-León Government (CSI049U16), the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R), Worldwide Cancer Research (14-1248), the Ramón Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC). MD (BFU2014-52729-P), JMP (SAF2015-66015-R, PIE15/00076), and PMF-S (SAF2014-51813-R) are supported by MINECO grants. Spanish funding is partially supported by the European Regional Development Fund. LFL-M, JC, and SR-F were supported by funding from the Spanish Ministry of Education, Culture and Sports (LFL-M, FPU13/02923) and the MINECO (JC, CD15/00113; SR-F, BES-2013-063573).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of distinct maturation steps involved in human 40S ribosomal subunit biosynthesis

  • Nieto, Blanca
  • Gaspar, Sonia G.
  • Moriggi, Giulia
  • Pestov, Dimitri G.
  • Bustelo, Xosé R.
  • Dosil, Mercedes
Technical problems intrinsic to the purification of preribosome intermediates have limited our understanding of ribosome biosynthesis in humans. Addressing this issue is important given the implication of this biological process in human disease. Here we report a preribosome purification and tagging strategy that overcomes some of the existing technical difficulties. Using these tools, we find that the pre-40S precursors go through two distinct maturation phases inside the nucleolus and follow a regulatory step that precedes late maturation in the cytoplasm. This regulatory step entails the intertwined actions of both PARN (a metazoan-specific ribonuclease) and RRP12 (a phylogenetically conserved 40S biogenesis factor that has acquired additional functional features in higher eukaryotes). Together, these results demonstrate the usefulness of this purification method for the dissection of ribosome biogenesis in human cells. They also identify distinct maturation stages and metazoan-specific regulatory mechanisms involved in the generation of the human 40S ribosomal subunit., M.D. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (BFU2014-52729-P, BFU2017-88192-P) and the Samuel Solórzano Foundation (FS/36-2017). X.R.B. is supported by grants from the Castilla-León Government (CSI049U16), the Spanish Ministry of Science, Innovation and Universities (SAF2015-64556-R), Worldwide Cancer Research (14-1248), the Ramón Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC). B.N. and G.M. have been supported by predoctoral contracts sponsored by the University of Salamanca and Santander Bank, and S.G.G. by a predoctoral FPU contract of the Spanish Ministry of Education, Culture, and Sports. The Centro de Investigación del Cáncer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Ministry of Education of the Castilla-León Government (CLC-2017-01). Both Spanish and Castilla-León government-associated funding is partially supported by the European Regional Development Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma

  • Lorenzo-Martín, L. Francisco
  • Fernández-Parejo, Natalia
  • Menacho-Márquez, Mauricio
  • Rodríguez-Fdez, Sonia
  • Robles-Valero, Javier
  • Zumalave, Sonia
  • Salvatore, Fabbiano
  • Pascual, Gloria
  • García-Pedrero, Juana María
  • Abad, Antonio
  • García-Macías, Carmen
  • González, Nazareno
  • Lorenzano Menna, Pablo
  • Pavón, Miguel A.
  • González-Sarmiento, Rogelio
  • Segrelles, Carmen
  • Paramio, Jesús M.
  • Tubío, José M. C.
  • Rodrigo, Juan Pablo
  • Benitah, Salvador A.
  • Cuadrado, Myriam
  • Bustelo, Xosé R.
© The Author(s) 2020., Regenerative proliferation capacity and poor differentiation are histological features usually linked to poor prognosis in head and neck squamous cell carcinoma (hnSCC). However, the pathways that regulate them remain ill-characterized. Here, we show that those traits can be triggered by the RHO GTPase activator VAV2 in keratinocytes present in the skin and oral mucosa. VAV2 is also required to maintain those traits in hnSCC patient-derived cells. This function, which is both catalysis- and RHO GTPase-dependent, is mediated by c-Myc- and YAP/TAZ-dependent transcriptomal programs associated with regenerative proliferation and cell undifferentiation, respectively. High levels of VAV2 transcripts and VAV2-regulated gene signatures are both associated with poor hnSCC patient prognosis. These results unveil a druggable pathway linked to the malignancy of specific SCC subtypes., We thank M. Blázquez and CIC facilities’ personnel for lab work and core unit technical assistance, respectively. X.R.B. is supported by grants from Worldwide Cancer Research (14-1248), the Castilla-León Government (CSI049U16, CLC-2017-01), the Spanish Ministry of Science and Innovation (MSI) (SAF2015-64556-R, RTI2018-096481-B-I00), the Ramón Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC). X.R.B.’s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Ministry of Education of the Castilla-León Government (CLC-2017-01). J.M.P. is supported by MSI grants (SAF2015-66015-R, PIE15/00076). S.A.B. was supported by the European Research Council, the Spanish MSIU, and the IRB-Barcelona. S.R.-F. and L.F. L.-M. contracts have been supported by funding from the MSI (BES-2013-063573) and the Spanish Ministry of Education, Culture, and Sports (L.F.L.-M., FPU13/02923), respectively. Both Spanish and Castilla-León government-associated funding is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HERC Ubiquitin Ligases in Cancer

  • Sala-Gaston, Joan
  • Martinez-Martinez, Arturo
  • Pedrazza, Leonardo
  • Lorenzo-Martín, L. Francisco
  • Caloto, Rubén
  • Bustelo, Xosé R.
  • Ventura, Francesc
  • Rosa, José Luis
© 2020 by the authors., HERC proteins are ubiquitin E3 ligases of the HECT family. The HERC subfamily is composed of six members classified by size into large (HERC1 and HERC2) and small (HERC3–HERC6). HERC family ubiquitin ligases regulate important cellular processes, such as neurodevelopment, DNA damage response, cell proliferation, cell migration, and immune responses. Accumulating evidence also shows that this family plays critical roles in cancer. In this review, we provide an integrated view of the role of these ligases in cancer, highlighting their bivalent functions as either oncogenes or tumor suppressors, depending on the tumor type. We include a discussion of both the molecular mechanisms involved and the potential therapeutic strategies., J.L.R. is supported by the Spanish Ministry of Science and Innovation (BFU2016-80295-R, SAF2017-90900-REDT, and UBIRed). X.R.B. is supported by grants from the Castilla-León Government (CSI252P18, CLC-2017-01), the Spanish Ministry of Science and Innovation (SAF2015-64556-R, RTI2018-096481-B-100) and the Spanish Association against Cancer (GC16173472GARC). X.R.B.’s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Castilla-León autonomous government (CLC-2017-01). Both Spanish and Castilla-León government-associated funding is partially supported by the European Regional Development Fund. J.S.-G. and A.M.-M. received FPU Fellowships (FPU17/02413 and FPU18/06325, respectively) from the Spanish Ministry of Science, Innovation and Universities.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAC1 induces nuclear alterations through the LINC complex to enhance melanoma invasiveness

  • Colón-Bolea, Paula
  • García-Gómez, Rocío
  • Shackleton, Sue
  • Crespo, Piero
  • Bustelo, Xosé R.
  • Casar, Berta
© 2020 Colón-Bolea et al., RHO GTPases are key regulators of the cytoskeletal architecture, which impact a broad range of biological processes in malignant cells including motility, invasion, and metastasis, thereby affecting tumor progression. One of the constraints during cell migration is the diameter of the pores through which cells pass. In this respect, the size and shape of the nucleus pose a major limitation. Therefore, enhanced nuclear plasticity can promote cell migration. Nuclear morphology is determined in part through the cytoskeleton, which connects to the nucleoskeleton through the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex. Here, we unravel the role of RAC1 as an orchestrator of nuclear morphology in melanoma cells. We demonstrate that activated RAC1 promotes nuclear alterations through its effector PAK1 and the tubulin cytoskeleton, thereby enhancing migration and intravasation of melanoma cells. Disruption of the LINC complex prevented RAC1-induced nuclear alterations and the invasive properties of melanoma cells. Thus, RAC1 induces nuclear morphology alterations through microtubules and the LINC complex to promote an invasive phenotype in melanoma cells., B.C.’s laboratory is supported by a Retos Jóvenes Investigadores grant SAF2015-73364-JIN Ministerio de Ciencia, Innovación y Universidades (MICIU/AEI/FEDER, UE), a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)—MCIU, and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I). P.C is supported by grant SAF-2015 63638R (MINECO/FEDER, UE); by Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC), RD/12/0036/0033, and by Asociación Española Contra el Cáncer (AECC) grant GCB141423113. X.R.B. is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), MINECO (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and AECC (GC16173472GARC). Spanish funding to B.C., P.C., and X.R.B. is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An unexpected tumor suppressor role for VAV1a

  • Bustelo, Xosé R.
  • Lorenzo-Martín, L. Francisco
  • Cuadrado, Myriam
  • Fernández-Pisonero, Isabel
  • Robles-Valero, Javier
RHO GDP/GTP exchange factors, including VAV1, are considered key protumorigenic factors. Against this paradigm, we have found that VAV1 plays tumor suppressor roles by buffering NOTCH1 signals in thymocytes. The silencing of this pathway contributes to the pathogenesis of T cell acute lymphoblastic leukemia of the early cortical, TLX+ subtype., Castilla-Leon Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramon Areces Foundation, and Spanish Society against Cancer (GC16173472GARC). Spanish governmental funding is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cancertool: A visualization and representation interface to exploit cancer datasets

  • Cortázar, Ana R.
  • Torrano, Verónica
  • Martín-Martín, Natalia
  • Caro-Maldonado, Alfredo
  • Camacho, Laura
  • Hermanova, Ivana
  • Guruceaga, Elizabeth
  • Lorenzo-Martín, L. Francisco
  • Caloto, Rubén
  • Gomis, Roger R.
  • Apaolaza, Iñigo
  • Quesada, Víctor
  • Trka, Jan
  • Gómez-Muñoz, Antonio
  • Vincent, Silvestre
  • Bustelo, Xosé R.
  • Planes, Francisco J.
  • Aransay, Ana M.
  • Carracedo, Arkaitz
With the advent of OMICs technologies, both individual research groups and consortia have spear-headed the characterization of human samples of multiple pathophysiologic origins, resulting in thousands of archived genomes and transcriptomes. Although a variety of web tools are now available to extract information from OMICs data, their utility has been limited by the capacity of nonbioinformatician researchers to exploit the information. To address this problem, we have developed CANCERTOOL, a web-based interface that aims to overcome the major limitations of public transcriptomics dataset analysis for highly prevalent types of cancer (breast, prostate, lung, and colorectal). CANCERTOOL provides rapid and comprehensive visualization of gene expression data for the gene(s) of interest in well-annotated cancer datasets. This visualization is accompanied by generation of reports customized to the interest of the researcher (e.g., editable figures, detailed statistical analyses, and access to raw data for reanalysis). It also carries out gene-to-gene correlations in multiple datasets at the same time or using preset patient groups. Finally, this new tool solves the time-consuming task of performing functional enrichment analysis with gene sets of interest using up to 11 different databases at the same time. Collectively, CANCERTOOL represents a simple and freely accessible interface to interrogate well-annotated datasets and obtain publishable representations that can contribute to refinement and guidance of cancer-related investigations at all levels of hypotheses and design., We are grateful to Iñaki Lazaro for the design of the tumor type logos, Evarist Planet and Antoni Berenguer for insightful discussions, and the Carracedo lab for valuable input. V. Torrano is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia and the Basque Department of Health (2016111109). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the Department of Education (IKERTALDE IT1106-16, also participated by A. Gomez-Muñoz), the BBVA Foundation, the MINECO [SAF2016-79381-R (FEDER/EU)]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks (SAF2016-81975-REDT), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC IDEAS16 (IDEAS175CARR), and the European Research Council (Starting Grant 336343, PoC 754627). CIBERONC was cofunded with FEDER funds. The work of A. Aransay is supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia County, CIBERehd Network, and Spanish MINECO the Severo Ochoa Excellence Accreditation (SEV-2016-0644). I. Apaolaza is funded by a Basque Government predoctoral grant (PRE_2017_2_0028). X.R. Bustelo is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO; SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and the Spanish Society against Cancer (GC16173472GARC). Funding from MINECO to X.R. Bustelo is partially contributed by the European Regional Development Fund. The work of F.J. Planes is supported by the MINECO (BIO2016-77998-R) and ELKARTEK Programme of the Basque Government (KK-2016/00026).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Genetic analysis of the role of vav oncoproteins in cancer

  • Bustelo, Xosé R.
  • Cuadrado, Myriam
  • Robles-Valero, Javier
  • Lorenzo-Martín, L. Francisco
Trabajo presentado en el Meeting Small G proteins in cellular signalling and disease, celebrado en Cambridge (Reino Unido) del 09 al 12 de julio de 2018., Rho GDP/GTP exchange factors (GEFs) are enzymes that promote the activation of Rho GTPases in both normal and cancer cells. Due to this, it is widely assumed that they can represent potential anticancer drug targets. However, we still have very little information about the actual role of these enzymes in human cancer, the therapeutic effectiveness of inhibiting their enzyme activities, and the side effects that such inhibition elicits in healthy tissues. Our group is trying to address these issues using as main tool the three known members of the Vav GEF family, the proteins Vav1, Vav2 and Vav3. To this end, we are utilizing a multifaceted approach based on the use of genetically modified mice, genome wide expression profiling techniques, cross-species transcriptomal comparisons, and patient-derived cell models. In my talk, I will present recent data demonstrating that the endogenous wild type and mutant versions of these proteins play proactive roles in mature T cell leukemia and a variety of epithelial tumors. Furthermore, I will discuss data from our “pharmaco-mimetic” knock-in mice demonstrating that the inhibition of GEFs does have a negative impact on the fitness of tumor cells in vivo., This work has been supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-64556-R), the Castilla-León Government (CSI049U16), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation

  • Casar, Berta
  • Badrock, Andrew P.
  • Jiménez, Iñaki
  • Arozarena, Imanol
  • Colón-Bolea, Paula
  • Lorenzo-Martín, L. Francisco
  • Barinaga-Rementería, Irene
  • Barriuso, Jorge
  • Cappitelli, Vincenzo
  • Donoghue, Daniel J.
  • Bustelo, Xosé R.
  • Hurlstone, Adam
  • Crespo, Piero
© The Author(s) 2018., RAS GTPases are frequently mutated in human cancer. H- and NRAS isoforms are distributed over both plasma-membrane and endomembranes, including the Golgi complex, but how this organizational context contributes to cellular transformation is unknown. Here we show that RAS at the Golgi is selectively activated by apoptogenic stimuli and antagonizes cell survival by suppressing ERK activity through the induction of PTPRκ, which targets CRAF for dephosphorylation. Consistently, in contrast to what occurs at the plasma-membrane, RAS at the Golgi cannot induce melanoma in zebrafish. Inactivation of PTPRκ, which occurs frequently in human melanoma, often coincident with TP53 inactivation, accelerates RAS-ERK pathway-driven melanomagenesis in zebrafish. Likewise, tp53 disruption in zebrafish facilitates oncogenesis driven by RAS from the Golgi complex. Thus, RAS oncogenic potential is strictly dependent on its sublocalization, with Golgi complex-located RAS antagonizing tumor development., We are grateful to Drs: Ignacio Rubio, Yardena Samuels, Mariano Barbacid and Javier León for providing reagents; and Alicia Noriega, Sandra Zunzunegui y Victor Campa for technical support. Crespo laboratory is supported by grant SAF-2015 63638R (MINECO/ FEDER, UE); by Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033 and by Asociación Española Contra el Cáncer (AECC), grant GCB141423113. Work in the Hurlstone laboratory was unded by a grant from the European Research Council (ERC-2011-StG-282059 PROMINENT). B.C. is supported by a Retos Jóvenes Investigadores grant SAF2015-73364-JIN (AEI/FEDER, UE) and a grant from Fundación Francisco Cobos. X.R.B. is supported by grants from the CastillaLeón Government (BIO/SA01/15, CSI049U16), MINECO (SAF2015-64556-R, RD12/ 0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, andAECC (GC16173472GARC). Spanish funding to P.C., B.C., and X.R.B. is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges

  • Bustelo, Xosé R.
  • Crespo, Piero
  • Fernández-Pisonero, Isabel
  • Rodríguez-Fdez, Sonia
Deregulated RAS signaling is associated with increasing numbers of congenital diseases usually referred to as RASopathies. The spectrum of genes and mutant alleles causing these diseases has been significantly expanded in recent years. This progress has triggered new challenges, including the origin and subsequent selection of the mutations driving these diseases, the specific pathobiological programs triggered by those mutations, the type of correlations that exist between the genotype and the clinical features of patients, and the ancillary genetic factors that influence the severity of the disease in patients. These issues also directly impinge on the feasibility of using RAS pathway drugs to treat RASopathy patients. Here, we will review the main developments and pending challenges in this research topic., The authors wish to apologize to scientists who have not been cited in this work due to space constraints. XRB work is supported by grants from the Castilla-León Government (CSI049U16), Spanish Ministry of Economy and Competitiveness (SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society against Cancer (GC16173472GARC). PC work is supported by grants from both the Spanish Ministry of Economy and Competitiveness (SAF-2015 63638R) and the Spanish Society against Cancer (GCB141423113). Funding from Spanish national and regional governments to both XRB and PC is partially contributed by the European Regional Development Fund.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia

  • Robles-Valero, Javier
  • Lorenzo-Martín, L. Francisco
  • Menacho Márquez, Mauricio
  • Fernández-Pisonero, Isabel
  • Abad, Antonio
  • Camós, Mireia
  • Toribio, María Luisa
  • Espinosa Blay, Lluís
  • Bigas Salvans, Anna
  • Bustelo, Xose R.
Rho guanine exchange factors (GEFs), the enzymes that stimulate Rho GTPases, are deemed as potential therapeutic targets owing to their protumorigenic functions. However, the understanding of the spectrum of their pathobiological roles in tumors is still very limited. We report here that the GEF Vav1 unexpectedly possesses tumor-suppressor functions in immature T cells. This function entails the noncatalytic nucleation of complexes between the ubiquitin ligase Cbl-b and the intracellular domain of Notch1 (ICN1) that favors ICN1 ubiquitinylation and degradation. Ablation of Vav1 promotes ICN1 signaling and the development of T cell acute lymphoblastic leukemia (T-ALL). The downregulation of Vav1 is essential for the pathogenesis of human T-ALL of the TLX+ clinical subtype, further underscoring the suppressor role of this pathway, X.R.B. is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R, RD12/0036/0002), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and Spanish Society Against Cancer. L.E. (PI13/00448), A.B. (SAF2013-40922-R, RD12/0036/0054), and M.L.T. (SAF2013-44857-R, RD12/0036/0075) are supported by MINECO grants. Spanish funding is partially supported by the European Regional Development Fund. We thank M. Blázquez for laboratory work, R. Valiente for ChIP-seq analyses, M. Dosil for comments on the manuscript, and CIC facilities' personnel for technical assistance
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia

  • Robles-Valero, Javier
  • Lorenzo-Martín, L. Francisco
  • Menacho-Márquez, Mauricio
  • Fernández-Pisonero, Isabel
  • Abad, Antonio
  • Camós, Mireia|||0000-0003-3658-7942
  • Toribio, María L.|||0000-0002-8637-0373
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Bustelo, Xosé R.
Rho guanine exchange factors (GEFs), the enzymes that stimulate Rho GTPases, are deemed as potential therapeutic targets owing to their protumorigenic functions. However, the understanding of the spectrum of their pathobiological roles in tumors is still very limited. We report here that the GEF Vav1 unexpectedly possesses tumor-suppressor functions in immature T cells. This function entails the noncatalytic nucleation of complexes between the ubiquitin ligase Cbl-b and the intracellular domain of Notch1 (ICN1) that favors ICN1 ubiquitinylation and degradation. Ablation of Vav1 promotes ICN1 signaling and the development of T cell acute lymphoblastic leukemia (T-ALL). The downregulation of Vav1 is essential for the pathogenesis of human T-ALL of the TLX + clinical subtype, further underscoring the suppressor role of this pathway. Robles-Valero et al. find that Vav1 facilitates binding of Cbl-b to the intracellular domain of Notch1 (ICN1) and promotes ICN1 degradation. Loss of Vav1 induces T cell acute lymphoblastic leukemia (T-ALL) by increasing ICN1 signaling, and TLX inhibits Vav1 expression to stimulate ICN1 signaling in TLX + T-ALL.